Back to Journals

Cancer Management and Research

ISSN: 1179-1322

Dr Kenan Onel

Dr Onel

Center for Precision Oncology and Cancer Prevention, Roswell Park Comprehensive Cancer Center, New York, NY, USA

Dr. Kenan Onel is an expert in clinical cancer genetics and oversees an active research program to investigate the role of genetics in cancer risk and response to therapy. He is a graduate of Yale University and received both an MD and a PhD in molecular biology from Cornell University Medical College. He completed a residency in Pediatrics at Babies and Children's Hospital of New York (Columbia University), a clinical fellowship in Pediatric Hematology/Oncology at the Memorial Sloan-Kettering Cancer Center, and a post-doctoral fellowship in Cancer Genetics at Rockefeller University. Dr. Onel then joined the faculty of The University of Chicago in 2004 where he was an Associate Professor of Pediatrics and Director of the Familial Cancer Clinic.

In 2016, Dr. Onel was recruited to the Zucker School of Medicine at Hofstra/Northwell where he was Professor of Pediatrics and Genetics and Chief of Medical Genetics and Human Genomics. In 2019, Dr. Onel joined the Icahn School of Medicine at Mount Sinai as Professor of Genetics and Genomic Sciences, and Associate Director of the Tisch Cancer Institute for Clinical Cancer Genetics and Precision Oncology.

In December 2023, Dr. Onel joined Roswell Park Comprehensive Cancer Center as Chief of Clinical Genomics and as the founding Director of the Center for Precision Oncology and Cancer Prevention.

Dr Antonella D'Anneo

Dr D'Anneo

Department of Biological, Chemical and Pharmaceutical Sciences and Technologies, University of Palermo, Palermo, Italy

Dr. D'Anneo earned a Master Degree with full marks and honors in Biological Sciences (curriculum in molecular biology) from the University of Palermo in 2000 and obtained a Ph.D. in Experimental Oncobiology in 2004. She began her studies on the field of tumor biology, cell death mechanisms and biochemical pathways that can be activated in tumor cells. Her scientific production is characterized by manuscripts on researches performed to elucidate the mode of action of apoptotic drugs and the possible synergistic interactions when drugs are employed in combination studies. To complement the graduate training in biochemistry, Dr. D'Anneo obtained, as visiting scholar, a training at Rangos Research Center (Children's Hospital, School of Medicine, University of Pittsburgh, PA-USA). During this stage (2005-2007), she was directly involved in the study of Adenoviral and EIA (Equine infectious anemia) viruses in blocking cytokine-induced apoptosis in both human and murine pancreatic ß islets. She also took part in a research project concerning gene therapy approaches to determine tolerization of diabetic patients against the cells of islet donor.

During her career, she has acquired expertise in the study of many different types of cell death (apoptosis, necrosis, necroptosis, autophagy and anoikis) activable in vitro tumor systems and the role of oxidative stress in cancer. Dr. D'Anneo made significant contributions to researches on combinations of sesquiterpene lactones (parthenolide), HDAC inhibitors (SAHA, Trichostatin A and sodium butyrate), proteasome inhibitors (MG132, lactacystin and Velcade) and recombinant Trail in vitro studies for the treatment of many different cancer systems. She is also the co-inventor of a patent for combined therapies for the treatment of liver tumors. In recent years she was also focused on the study of the serpin proteinase inhibitor 9 (PI-9) in ER+ breast cancer cells and breast cancer stem-like cells.

She is currently an Assistant Professor in Biochemistry at the Department of Sciences and Biological, Chemical and Pharmaceutical Technologies, School of Basic and Applied Sciences, University of Palermo and serves as mentor of PhD and students of the MSc in Molecular and Health Biology.

Professor Bilikere Dwarakanath

Professor Dwarakanath

Indian Academy Degree College-Autonomous, Bengaluru, India

Dr. Dwarakanath is an expert in radiation biology and has worked extensively in the areas of targeting metabolic reprogramming for improving radio- and chemotherapy of cancer and radiation countermeasures. He is a graduate of National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India and received a PhD in biophysics from Bangalore University, Bangalore, India in 1988. He pursued a post-doctoral fellowship from 1989 until 1991 at Bowman Gray School of Medicine of the Wake Forest University, North Carolina, USA in the laboratory of Kenneth Wheeler, a renowned radiation biologist.

Dr. Dwarakanath served at NIMHANS until 1994 before moving to Institute of Nuclear Medicine and Allied Sciences (INMAS), Delhi where he worked as a scientist at different levels and Additional Director until 2015. In 2015, Dr. Dwarakanath joined Sri Ramachandra University (SRU, currently known as SRIHER), Chennai, India as Professor and worked in the Central Research facility. In September 2017, Dr. Dwarakanath moved to Shanghai Proton and Heavy Ion Center, Shanghai, China as Senior Principal Investigator. Currently, he is associated with the Indian Academy Degree College–Autonomous, Bengaluru, India as a Research Advisor.

Dr Ahmet Emre Eşkazan

Dr Eşkazan

Department of Internal Medicine, Division of Hematology, Istanbul University-Cerrahpaşa, Istanbul, Turkey

Dr. Eskazan is an Associate Professor of Internal Medicine/Hematology. He obtained his MD from Cerrahpaşa Faculty of Medicine, Istanbul University in 1999. He finished an internal medicine residency and hematology fellowship at the same institution in 2005 and 2010, respectively. His research interests have been focussed on chronic myeloid leukemia, acute myeloid leukemia, and other myeloproliferative neoplasms. In 2015, he worked as a visiting physician at the University of Texas, MD Anderson Cancer Center, Department of Leukemia.

Dr. Eskazan has more than 90 papers published in peer reviewed journals. He is currently working at the Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa.

Dr Alexandra R. Fernandes

Dr Fernandes

UCIBIO—Applied Molecular Biosciences Unit, Department of Life Sciences, NOVA School of Science and Technology, Caparica, Portugal

Dr. Fernandes is an Assistant Professor at Faculty of Science and Technology, NOVA University of Lisbon, Portugal. She obtained her PhD in Biotechnology from Instituto Superior Técnico, Universidade de Lisboa after earning her graduation degree in Chemical Engineering/Biotechnology also from the same institution in Lisbon, Portugal.

Dr. Fernandes is an expert research scientist that combines chemistry, biochemistry, molecular biology and human molecular genetics. Her research interests have been focussed on cancer diagnostics, biomarkers identification and validation, drug screen and validation using in vitro and in vivo models and in the development of novel combinatorial therapies. In 2013, she has translated part of her research into a private Diagnostics company.

Dr. Fernandes has 5 book chapters, and more than 65 papers published in peer reviewed journals. Dr. Fernandes serves as reviewer for more than 8 reputable journals.

Professor Kattesh Katti

Professor Katti

Institute of Green Nanotechnology and Cancer Nanotechnology, Department of Radiology, University of Missouri, Columbia, MO, USA

Professor Kattesh V. Katti is globally recognized as the 'Father of Green Nanotechnology' which has implications in oncology, antibiotics and antivirals. He received a PhD from the Indian Institute of Science, Bangalore, India. He is the recipient of the prestigious Alexander Von Humboldt fellowship for his postdoctoral research at the University of Gottingen, Germany. He is currently a distinguished Curators’ Professor of Radiology, Director, Institute of Green Nanotechnology, within the Medical School, University of Missouri, Columbia, USA. 

Over the last three decades, he is actively involved in research within the interconnecting fields of — chemistry, radiopharmaceutical sciences, nanotechnology/green nanotechnology and nanomedicine — for biomedical applications, specifically for molecular imaging and therapy of living subjects. He is an inventor of a new medical modality called as 'Nano-Ayurvedic Medicine' — a new medical modality which he has discovered by the application of Green Nanotechnology to Ayurvedic-Holistic Medicine. The US Patents and Trademarks office has approved the use of 'Nano-Ayurvedic Medicine' name in the products of this new medical modality. Several cancer therapy products, antiviral agents and antibiotics, discovered by him are currently used in treating human patients.

He has been awarded a number of international awards, recognitions and citations, which include: United Nations/IAEA’s Global Expert in 'Green Nanotechnology', 'Person of the Year in Science', International Hevesy Medal Award, one of the '25 Most Influential Scientists In Molecular Imaging in the World' award by RT Image, 'Father of Green Nanotechnology' citation by the Nobel Prize Winner Norman Borlaug and has been bestowed with the Gauss Professorship—Hall of Fame—from the Gottingen Academy of Sciences. Professor Katti is the first immigrant American to win the 'Outstanding Missourian Award' — the highest civilian award from the Governor of the State of Missouri. He is an elected fellow of the National Academy of Inventors - recognizing the discovery of 'Katti Peptides' — a group of peptides used in biomedical sciences and nanomedicine product development. Professor Katti is also an elected fellow in the College of American Institute of Medical and Biological Engineering (AIMBE). He is also an elected fellow of the American Association for the Advancement of Science (AAAS) and a Fellow of the St Louis Academy of Science (more awards and recognitions can be viewed here).

Dr Chien-Feng Li

Dr Li

National Institute of Cancer Research, National Health Research Institutes, Tainan, Taiwan

Dr. Li is the Chair of Department of Pathology, Chi Mei Medical Center, and he also serves as a professor at Southern Taiwan University of Science and Technology, as well as a joint-appointment associate investigator at National Institute of Cancer Research (Taiwan). He got his Medical Degree from Kaohsiung Medical University in 2002. In 2012, he got his Doctor of Philosophy in biomedical sciences from National Sun Yat-sen University. As a physician scientist, his current research interest is integrative analysis of genetic, epigenetic, and expression alternations during cancer progression and metastasis, with special emphasis on sarcomas and therapy-resistant cancers. With the opportunities to integrate large-scaled clinical samples and advanced functional evaluations, he has been more focused on potential therapeutic opportunities of oncogenic metabolic transformations and the mechanisms how the metabolic characters of cancer implicate tumor progression.

Professor Harikrishna Nakshatri

Professor Nakshatri

Professor of Surgery, Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, USA

Harikrishna Nakshatri, B.V.Sc., Ph.D., is the Marian J. Morrison Chair of Breast Cancer Research and Professor of Surgery, Biochemistry and Molecular Biology at the Indiana University School of Medicine. He is also the Associate Director for Education at the Indiana University Simon Comprehensive Cancer Center. He serves as a Research Career Scientist at the VA Roudebush Medical center. In addition, he is the Chief Scientific Officer of the Susan G. Komen Tissue Bank. He served as a Susan G. Komen Scholar 2010-2020 and was elected as a Fellow of the American Association for the Advancement of Sciences (AAAS) in 2021.

Dr. Nakshatri studies the molecular drivers of therapy resistance in breast cancer. His laboratory was the first to identify the role of the protein complex, NF-kappaB, which controls genes that respond to environmental stress and infection, in triple negative breast cancer. He also identified biomarkers that may predict response to anti-estrogen therapy. Utilizing normal breast tissues of women of different ethnic/racial background, his group has discovered genetic ancestry-dependent heterogeneity in the normal breast, which has important implications on how tumors are characterized for genomic abnormalities. His recently published studies may enable to understand why hormone-responsive breast tumors are more common in women of European ancestry and why triple negative breast cancers are aggressive in women of African ancestry. Additionally, his group has mapped the normal breasts as well as the breasts of BRCA1/2 mutation careers at single cell resolution using single cell sequencing techniques. These efforts may lead to classification of breast cancer based on “cell-of-origin” of tumor. He is using systems biology approaches to understand organ specific breast cancer metastasis and developing patient-derived tumor models that reflect organ-specific metastasis and therapy resistance.

Professor Seema Singh

Professor Singh

Department of Pathology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Professor Singh's primary research expertise is in the field of breast cancer, pancreatic cancer and melanoma. Specifically, her lab is interested in understanding the biological connection of inflammation and cancer. They have major emphasis on the role of inflammatory cytokines in cancer progression, metastasis and therapy resistance. Also investigating molecular pathways in the regulatory networks of these cytokines and underlying causes of their dysregulation. Another area of research emphasis in her lab is to unveil the biological basis of cancer health disparities. Her current appointment is at the Department of Pathology, Mitchell Cancer Institute, University of South Alabama.

Dr Sanjeev K. Srivastava

Dr Srivastava

Department of Pathology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA

Dr. Sanjeev K. Srivastava is an Assistant Professor at the University of South Alabama Mitchell Cancer Institute (USAMCI). Dr. Srivastava received his Ph.D. in Human Genetics in 2007, and completed his post-doctoral trainings at the Semmelweis Medical University, Budapest, Hungary and USAMCI.

Dr. Srivastava is engaged in a number of research programs that encompass the areas of breast cancer, pancreatic cancer, prostate cancer, ovarian cancer and melanomas, to identify novel deregulated genes and dissect their underlying regulatory pathways and functional significance. He has published more than 45 international peer-reviewed articles, authored 5 book chapters, and has been the recipient of an international patent. He is a recipient of two NIH/NCI-Small Business Innovation Research (SBIR) Phase I funding for advancing cancer health disparity research. He is also a co-Principal investigator on several NIH/NCI (R01) grant.

Professor Lu-Zhe Sun

Professor Sun

Department of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Dr. Lu-Zhe Sun received his Ph.D. in Physiology from Rutgers University and UMDNJ-Robert Wood Johnson Medical School in 1990 and obtained his postdoctoral training in Baylor College of Medicine in the US. He is currently Professor, Dielmann Endowed Chair in Oncology, and Associate Director for Basic Research at his NCI-designated cancer center.

Dr. Sun's research is focused on investigating molecular mechanisms of tumorigenesis and metastasis, and novel experimental therapeutics in various models of carcinomas. His research has been supported with multi-million dollar grants from NIH, DOD, CPRIT, and other private foundations. He is an elected AAAS Fellow.

Dr Beicheng Sun

Dr Sun

Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

Dr. Sun is a professor and surgeon at Nanjing University where he serves as the Vice president of The Affiliated Drum Tower Hospital of Nanjing University Medical School. In 2001, he obtained his MD-PhD degree in Nanjing Medical University, China. As a postdoctoral fellow at The University of Texas Health Science Center at San Antonio, he devoted his time to telomerase-related cancer research. As a surgeon, he is skilled in liver transplantation and Hepatectomy.

Dr. Sun's research is mainly focused on inflammatory-related carcinogenesis. His team discovered the potential therapeutic values and mechanistic roles of cytokines in hepatocarcinogenesis including IL-22, IL-17A, and IL-1α, etc. His team also explored the cell signaling involving in the malfunction of tumor infiltrated Leucocytes (TILs), they clarified the roles of PTPRO/STAT3, PTPRO/NF-κB, and Lnc-EGFR/EGFR/AP-1 signaling in the immunosuppressive-transform of T cell and macrophage. His current research interests are inflammatory related metabolic disorders in TILs, aiming to clarify the metabolism-related links in T cell exhausting and NK cell malfunction. Meanwhile, clinical trials of immunotherapy are in procession using CAR-T and CRISPR-Cas9. 

Dr. Sun is the Yangtze River Scholar Professor of Chinese Ministry of Education, and he also obtained a National Science Fund for Distinguished Young Scholars. He is an Associate Editor of Plos One and Associate Editor of World Journal of Gastroenterology, a member of the Youth Committee of Chinese Organ Transplantation Society of Chinese Medical Association and the Executive Committee of Chinese Society of Liver Cancer, Chinese Anti-Cancer Association. 

Professor Yong Teng

Professor Teng

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA

Dr. Yong Teng, PhD, is an associate professor of the Department of Hematology and Medical Oncology at Emory School of Medicine, USA. He is the inaugural recipient of Winship Cancer Institute Wally Award and a member of the BME Program Faculty, Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Tech. Dr. Teng is an active member of the International Head and Neck Scientific Group, the Royal Society of Medicine, American Association for Cancer Research and other associations. His research interests lie primarily in bridging three major research themes, tumor metabolism, microenvironment, and metastasis, with a special emphasis on several molecular determinants, and translating these discoveries into better therapeutics by integrating novel treatment strategies and drug delivery systems. His team has authored more than 150 articles and chapters relating to the mechanistic understanding of cancer progression, treatment responses, and anticancer drug action, providing a balanced mix of basic and translational science to shed new light on cancer management and research. His research has been funded by National Institutes of Health, Department of Defense, the industry, and other funding agencies. Dr. Teng also serves on a number of grant review panels, journal editorial boards and international conference committees, demonstrating his exceptional commitment to serving the scientific community.

Editorial Board

Dr Oronzo Brunetti, Medical Assistance – Medical Oncology Unit, National Cancer Institute, Italy.

Prof. Franky Leung Chan, Professor, Cancer Biology and Experimental Therapeutics, School of Biomedical Sciences, Chinese University of Hong Kong, Shatin, Hong Kong

Damiano Chiari, MD, Department of General Surgery, Humanitas Mater Domini Clinical Institute, Humanitas University, Italy

Professor Brendon Coventry, Associate Professor of Surgery, Discipline of Surgery, University of Adelaide, Royal Adelaide Hospital, South Australia, Australia 5000

Alfio Ferlito, Professor of Otorhinolaryngology-Head and Neck Surgery, Coordinator of the International Head Neck Scientific Group (

Gary L Johanning, Chief Scientific Officer, SunnyBay Biotech, USA.

Cheryl L. Jorcyk, Director, Clinical & Translational Research; Professor, Biological Sciences, Boise State University, Boise, ID, USA. Dr. Jorcyk's lab investigates the role of inflammatory cytokines in breast cancer invasion and metastasis.

Evan Keller, Professor, Department of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA

Silvana Morello, PhD, Assistant Professor of Clinic Pharmacology and Immunopharmacology, Department of Pharmacy, University of Salerno, Salerno, Italy.

Birija Sankar Patro, Head, Bio-Organic Division, Mod. Lab, Bhabha Atomic Research Centre, Mumbai, India. 

Errol Philip, Notre Dame Laboratory for Psycho-oncology Research, University of Notre Dame, Notre Dame, IN, USA

Dr. Santosh Kumar Singh, Ph.D., Department of Microbiology, Biochemistry & Immunology, Morehouse School of Medicine, Atlanta, GA, USA

Johnson Stanslas, Professor, Pharmacotherapeutics Unit, Department of Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Malaysia

Prof. Andrzej Stepulak, MD.Ph.D, Department of Biochemistry and Molecular Biology, Medical University in Lublin, Lublin, Poland.

Friedrich Stölzel, Professor, Department of Internal Medicine I, University Hospital Dresden, Germany

Dr. Basant Kumar Thakur, Principal Investigator (Exosome research lab), Department of Pediatric Hematology and Oncology, University Children's Hospital of Essen, University Hospital of Essen, Essen, Germany.

Kexin Xu, Assistant Professor, Department of Molecular Medicine, the University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Jing Zhang, Professor in Department of Pathology, State Key Laboratory of Tumor Biology, Xijing Hospital, Fourth Military Medical University, Xi’an, Shaanxi, China.

Guo Zhao, Clinical Trial Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Ho, Peking Union Medical College, China.